ClinicalTrials.gg
CompletedNCT00545584Updated May 12, 2017Results posted

Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)

A Phase 3 interventional study of sitagliptin phosphate and Comparator: Diet in Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Apr 2007, registered Oct 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,512
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
4th of 197
1,512 · median 102
Started
2007
with 16 others
Phase 3
74 of 198
none open now
Registered
37th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 74 in phase 3, and was the 37th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled by metformin (hemoglobin A1c [HbA1c] 6.5-9%). A difference between the three strategies of lifestyle changes was expected.

03

Conditions studied

  • Diabetes Mellitus, Non-Insulin-Dependent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man or woman aged >/= 18 years,with T2DM and treated with the maximal tolerated dose of metformin, with documented or high likely inadequate control of diabetes ( 6.5-9%)

Exclusion criteria

Exclusion Criteria:

  • Daily insulin treatment or one insulin dose or more within the last 8 weeks or expected insulin treatment within the next 3 months.
  • Hypoglycemia unawareness or recurrent major hypoglycemia or history of acidoketosis
  • Known or to metformin
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,512 participants (actual)

Study arms

  • Experimental
    Sitagliptin with Standard of Care

    Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: No specific intervention (standard recommendation) on physical exercise and diet.

    Drug: sitagliptin phosphate

  • Experimental
    Sitagliptin with Diet Advice

    Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: Intervention on diet which includes advice on diet with a leaflet and a diary

    Drug: sitagliptin phosphate · Behavioral: Comparator: Diet

  • Experimental
    Sitagliptin with Diet and Physical Activity Advice

    Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week.

    Drug: sitagliptin phosphate · Behavioral: Comparator: Diet · Behavioral: Comparator: Physical Activity

Interventions

  • DrugSitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks

  • BehavioralComparator: Diet

    Diet

  • BehavioralComparator: Physical Activity

    Physical Activity

06

What researchers measure

Primary outcomes

  1. Hemoglobin A1c Measurement

    Hemoglobin A1c (HbA1c) is a measure of glycated hemoglobin in the blood. HbA1c greater than 6.5% was considered inadequately controlled.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Fasting Plasma Glucose (FPG) Measurement

    Generally FPG values of \~5.0-7.2 mmol/L would be considered goal (American Diabetes Association).

    Time frame: Baseline and Week 24

07

Results

Posted May 11, 2011

Participant flow

Participant flow — Overall Study
MilestoneSitagliptin With Standard of CareSitagliptin With Diet AdviceSitagliptin With Diet and Physical Activity Advice
Started412414306
Completed333334250
Not completed798056
Withdrew: Only one reason for discontinuation626148
Withdrew: Two or more reasons for discontinuation17198

Outcome measures

PrimaryHemoglobin A1c Measurement

Hemoglobin A1c (HbA1c) is a measure of glycated hemoglobin in the blood. HbA1c greater than 6.5% was considered inadequately controlled.

Time frame:
Baseline and Week 24
Reported as:
Mean · percent HbA1c
Hemoglobin A1c Measurement
percent HbA1cSitagliptin With Standard of CareSitagliptin With Diet AdviceSitagliptin With Diet and Physical Activity Advice
Baseline (n=360, 358, and 265, respectively)7.37 ± 0.617.50 ± 0.667.49 ± 0.60
Week 24 (n=362, 358, and 265, respectively)7.33 ± 1.097.42 ± 1.157.40 ± 1.07
SecondaryFasting Plasma Glucose (FPG) Measurement

Generally FPG values of \~5.0-7.2 mmol/L would be considered goal (American Diabetes Association).

Time frame:
Baseline and Week 24
Reported as:
Mean · mmol/L glucose
Fasting Plasma Glucose (FPG) Measurement
mmol/L glucoseSitagliptin With Standard of CareSitagliptin With Diet AdviceSitagliptin With Diet and Physical Activity Advice
Baseline (n=350, 350, 252, respectively)8.87 ± 1.989.00 ± 2.038.91 ± 1.87
Week 24 (n=310, 303, and 224, respectively)8.21 ± 2.078.32 ± 2.088.47 ± 2.17

Adverse events

Collected over This safety data includes AEs and SAEs that occurred during treatment (Visit 2 to Visit 4).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin With Standard of Care—8/412 (1.9%)0/412 (0%)
Sitagliptin With Diet Advice—18/414 (4.3%)0/414 (0%)
Sitagliptin With Diet and Physical Activity Advice—7/305 (2.3%)0/305 (0%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventSitagliptin With Standard of CareSitagliptin With Diet AdviceSitagliptin With Diet and Physical Activity Advice
PROSTATE CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4120/4142/305
FRACTUREInjury, poisoning and procedural complications0/4120/4141/305
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/4120/4141/305
LUNG NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4120/4141/305
CERVICAL ROOT PAINNervous system disorders0/4120/4141/305
SCIATICANervous system disorders0/4120/4141/305
IDIOPATHIC THROMBOCYTOPENIC PURPURABlood and lymphatic system disorders1/4120/4140/305
ACUTE CORONARY SYNDROMECardiac disorders1/4121/4140/305
ADAMS-STOKES SYNDROMECardiac disorders1/4120/4140/305
INGUINAL HERNIAGastrointestinal disorders1/4120/4140/305

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin With Standard of CareSitagliptin With Diet AdviceSitagliptin With Diet and Physical Activity AdviceTotal
Mean58.26 ± 10.0457.47 ± 9.1257.30 ± 9.9057.71 ± 9.68
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin With Standard of CareSitagliptin With Diet AdviceSitagliptin With Diet and Physical Activity AdviceTotal
Female181175126482
Male181183139503
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2007 to primary completion in Nov 2009, 31 months.

Results were first posted in May 2011, 1 year 5 months after primary completion. A results delay was requested in Nov 2010.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 31 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2007
First posted
Oct 17, 2007
StartActual
Apr 1, 2007
Primary completionActual
Nov 19, 2009
CompletionActual
Nov 19, 2009
Results delay requested
Nov 18, 2010
Results first posted
May 11, 2011
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00545584
Responsible party
Sponsor
First posted
Oct 17, 2007
Start date
Apr 1, 2007
Primary completion
Nov 19, 2009
Completion
Nov 19, 2009
Results posted
May 11, 2011
Last update
May 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion